Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
Incyte (INCY) and Genesis Therapeutics have announced a strategic collaboration focused on developing novel small molecule medicines using Genesis' GEMS artificial intelligence platform. The partnership grants Incyte exclusive rights to develop and commercialize collaboration products.
Under the agreement, Genesis will receive a $30 million upfront payment and could earn up to $295 million in milestone payments per target. The collaboration initially focuses on two targets, with Incyte having the option to add a third target for a predetermined fee. Genesis is also eligible for tiered royalties on sales of approved collaboration products.
The partnership aims to leverage Genesis' proprietary AI technology, GEMS (Genesis Exploration of Molecular Space), to accelerate the discovery and optimization of small molecule compounds for Incyte-selected targets.
Incyte (INCY) e Genesis Therapeutics hanno annunciato una collaborazione strategica focalizzata sullo sviluppo di nuovi medicinali a piccole molecole utilizzando la piattaforma di intelligenza artificiale GEMS di Genesis. La partnership concede a Incyte diritti esclusivi per sviluppare e commercializzare i prodotti della collaborazione.
In base all'accordo, Genesis riceverà un pagamento iniziale di 30 milioni di dollari e potrebbe guadagnare fino a 295 milioni di dollari in pagamenti per traguardi per ogni obiettivo. La collaborazione si concentra inizialmente su due obiettivi, con Incyte che ha l'opzione di aggiungere un terzo obiettivo per una tariffa predeterminata. Genesis è inoltre idonea a ricevere royalties scalari sulle vendite dei prodotti approvati della collaborazione.
La partnership mira a sfruttare la tecnologia AI proprietaria di Genesis, GEMS (Genesis Exploration of Molecular Space), per accelerare la scoperta e l'ottimizzazione di composti a piccole molecole per obiettivi selezionati da Incyte.
Incyte (INCY) y Genesis Therapeutics han anunciado una colaboración estratégica centrada en el desarrollo de nuevos medicamentos de pequeñas moléculas utilizando la plataforma de inteligencia artificial GEMS de Genesis. La asociación otorga a Incyte derechos exclusivos para desarrollar y comercializar los productos de la colaboración.
Según el acuerdo, Genesis recibirá un pago inicial de 30 millones de dólares y podría ganar hasta 295 millones de dólares en pagos por hitos por cada objetivo. La colaboración se centra inicialmente en dos objetivos, con Incyte teniendo la opción de agregar un tercer objetivo por una tarifa predeterminada. Genesis también es elegible para recibir regalías escalonadas sobre las ventas de los productos aprobados de la colaboración.
La asociación tiene como objetivo aprovechar la tecnología de IA propietaria de Genesis, GEMS (Exploración Génesis del Espacio Molecular), para acelerar el descubrimiento y la optimización de compuestos de pequeñas moléculas para los objetivos seleccionados por Incyte.
Incyte (INCY)와 Genesis Therapeutics는 Genesis의 인공지능 플랫폼 GEMS를 사용하여 새로운 소분자 의약품 개발에 중점을 둔 전략적 협력을 발표했습니다. 이 파트너십은 Incyte에게 협력 제품을 개발하고 상업화할 수 있는 독점 권리를 부여합니다.
계약에 따라 Genesis는 3천만 달러의 선불 지급을 받고, 각 목표에 대해 최대 2억 9천 5백만 달러의 이정표 지급을 받을 수 있습니다. 협력은 처음에 두 개의 목표에 초점을 맞추며, Incyte는 정해진 수수료로 세 번째 목표를 추가할 수 있는 옵션을 가지고 있습니다. Genesis는 또한 승인된 협력 제품 판매에 대한 단계적인 로열티를 받을 자격이 있습니다.
이 파트너십은 Genesis의 독점 AI 기술인 GEMS(분자 공간의 탐색)를 활용하여 Incyte가 선택한 목표에 대한 소분자 화합물의 발견과 최적화를 가속화하는 것을 목표로 하고 있습니다.
Incyte (INCY) et Genesis Therapeutics ont annoncé une collaboration stratégique axée sur le développement de nouveaux médicaments à petites molécules utilisant la plateforme d'intelligence artificielle GEMS de Genesis. Ce partenariat accorde à Incyte des droits exclusifs pour développer et commercialiser les produits de la collaboration.
Dans le cadre de l'accord, Genesis recevra un paiement initial de 30 millions de dollars et pourrait gagner jusqu'à 295 millions de dollars en paiements d'étapes par cible. La collaboration se concentre initialement sur deux cibles, Incyte ayant la possibilité d'ajouter une troisième cible moyennant un tarif prédéterminé. Genesis est également éligible à des redevances échelonnées sur les ventes des produits approuvés de la collaboration.
Ce partenariat vise à tirer parti de la technologie d'IA propriétaire de Genesis, GEMS (Exploration Génétique de l'Espace Moléculaire), pour accélérer la découverte et l'optimisation de composés à petites molécules pour les cibles sélectionnées par Incyte.
Incyte (INCY) und Genesis Therapeutics haben eine strategische Zusammenarbeit angekündigt, die sich auf die Entwicklung neuer niedermolekularer Arzneimittel mithilfe der KI-Plattform GEMS von Genesis konzentriert. Die Partnerschaft gewährt Incyte exklusive Rechte zur Entwicklung und Vermarktung der Kooperationsprodukte.
Im Rahmen der Vereinbarung erhält Genesis eine Vorabzahlung von 30 Millionen Dollar und könnte bis zu 295 Millionen Dollar an Meilensteinzahlungen pro Ziel verdienen. Die Zusammenarbeit konzentriert sich zunächst auf zwei Ziele, wobei Incyte die Option hat, ein drittes Ziel gegen eine vorher festgelegte Gebühr hinzuzufügen. Genesis ist auch berechtigt, gestaffelte Lizenzgebühren auf den Verkauf genehmigter Kooperationsprodukte zu erhalten.
Die Partnerschaft zielt darauf ab, die proprietäre KI-Technologie von Genesis, GEMS (Genesis Exploration of Molecular Space), zu nutzen, um die Entdeckung und Optimierung von niedermolekularen Verbindungen für von Incyte ausgewählte Ziele zu beschleunigen.
- Secured exclusive rights to develop and commercialize AI-discovered drug candidates
- Access to cutting-edge AI platform for drug discovery acceleration
- Structured deal limits upfront financial exposure ($30M) while maintaining milestone-based incentives
- Significant potential milestone payments of up to $295M per target could impact future cash flow
- Success dependent on unproven AI technology platform
Insights
This strategic AI collaboration marks a pivotal shift in Incyte's R&D approach, demonstrating a calculated move to accelerate drug discovery through artificial intelligence. The
The deal's structure is particularly noteworthy for several reasons:
- The potential
$295 million in milestone payments per target provides Genesis with substantial upside while allowing Incyte to manage risk through performance-based compensation - The inclusion of two initial targets with an option for a third target offers strategic flexibility and pipeline diversification
- The tiered royalty structure aligns incentives for both parties throughout the commercialization phase
The collaboration's focus on small molecule therapeutics is strategically significant. Small molecules represent approximately
From a competitive standpoint, this partnership positions Incyte alongside industry leaders like Merck and Pfizer, who have made similar AI-focused investments. The GEMS platform's specific focus on challenging targets suggests potential applications in areas where traditional discovery methods have fallen short. This could provide Incyte with a significant advantage in addressing unmet medical needs and accessing new market opportunities.
The deal's structure and focus on small molecules indicate a well-considered strategy to enhance R&D efficiency while maintaining control over development and commercialization. Success in this collaboration could significantly impact Incyte's development timeline and cost structure, potentially reducing the time and resources required to bring new drugs to market.
- Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets
- Incyte receives exclusive rights to develop and commercialize collaboration products
Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis’ proprietary AI platform, GEMS (Genesis Exploration of Molecular Space), the partnership will pursue the discovery and optimization of small molecule compounds for the collaboration targets. Incyte is granted exclusive rights for potential clinical development and commercialization of collaboration products.
“As a leader in pharmaceutical innovation, Incyte is continually seeking new technologies that can transform how new medicines are discovered and developed,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the discovery of breakthrough small molecules for high-impact targets in our pipeline.”
“AI has the potential to redefine how we discover small molecule medicines, and our team is at the forefront of this revolution,” said Evan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis. “We are pleased to establish this world-class partnership to combine our GEMS AI platform with Incyte’s deep expertise and track record in drug discovery and development, with the shared goal of advancing critical treatments for patients with severe diseases.”
Terms of the Agreement
Under the terms of the agreement, Genesis will receive an upfront payment of
About Genesis Therapeutics
Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), for small molecule drug discovery. GEMS integrates proprietary AI methods, including language models, diffusion models and physical simulation, to generate and optimize molecules for complex targets. Genesis has raised over
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential of the products arising from the collaboration with Genesis Therapeutics, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte‘s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by regulatory authorities; Incyte‘s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte‘s products and the products of Incyte‘s collaboration partners; the acceptance of Incyte‘s products and the products of Incyte‘s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte‘s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220803826/en/
Genesis Media Contact:
Thermal for Genesis
press@genesistherapeutics.ai
Incyte Contacts:
Media
media@incyte.com
Investors
ir@incyte.com
Source: Genesis Therapeutics, Inc. and Incyte
FAQ
What is the value of Incyte's (INCY) upfront payment to Genesis Therapeutics?
How much could Genesis earn in milestone payments per target from INCY?
How many initial targets are included in the INCY-Genesis collaboration?
What rights does Incyte (INCY) receive in the Genesis partnership?
What technology platform will be used in the INCY-Genesis collaboration?
